

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: TruTrace Technologies Inc. (the "Issuer" or "TruTrace").

Trading Symbol: TTT

Number of Outstanding Listed Securities: 83,111,732

Date: November 6, 2019

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer entered into a letter of intent with Sigma Analytical Services ("Sigma Analytical"), a provider of comprehensive testing and analytical services for the cannabis industry, to establish a strategic working relationship. Pursuant to the letter of intent, the Issuer plans to include Sigma Analytical as a genetics verification and testing partner in its blockchain-secured traceability ecosystem, and the parties will explore development and integration opportunities to rapidly expedite and optimize testing processes in the cannabis and hemp industries. Sigma Analytical is also expected to participate in the Issuer's and Shoppers Drug Mart medical cannabis verification pilot program (the "Pilot Program") as a testing partner.

The Issuer also entered into a letter of intent with AdvancedCare, a leading clinical research, clinical and telemedicine platform used by medical professionals around the world, to begin a strategic working relationship to integrate their technologies. Pursuant to the letter of intent, AdvancedCare plans to integrate the Issuer's StrainSecure™ technology within its own platform, with the objective of providing product data directly to medical professionals, patients and researchers to ensure medication has been verified and is safe to consume. The AdvancedCare platform is used within both care plans and clinical research trials. In addition, the Issuer will include AdvancedCare as a preferred partner in its StrainSecure Ecosystem.

On October 24, 2019, the Issuer closed the first tranche of a non-brokered private placement financing (the "Financing") of secured convertible debentures (each, a "Debenture") pursuant to which the Issuer issued a Debenture in the principal amount of \$200,000 to one subscriber. On October 31, 2019, the Issuer closed the second tranche of the Financing pursuant to which the Issuer issued Debentures in the aggregate principal amount of \$75,000 to three subscribers.

The terms of the Debentures include:

- a maturity date of three years from the date of issuance (the "Maturity Date") and the principal amount of the Debentures, together with any accrued and unpaid Interest, will be payable on the Maturity Date, unless earlier converted in accordance with its terms;
- the Debentures bear interest (the "Interest") at the rate of 8.25% per annum, which Interest will be payable on maturity, unless earlier converted;
- the principal amount of the Debentures, together with all accrued and unpaid Interest thereon, is convertible into units of the Issuer (each, a "Debenture Unit"), at the option of the holders, at a conversion price of \$0.25 per Debenture Unit (the "Conversion Price"), with each Debenture Unit comprised of one common share of the Issuer (each, a "Debenture Share") and one transferable share purchase warrant (each, a "Debenture Warrant"), with each Debenture Warrant exercisable into one additional Debenture Share

(each, a “Debtenture Warrant Share”) at an exercise price of \$0.30 per Debtenture Warrant Share for a period equal to the later of: (i) ninety days from the date of conversion, or (ii) three years from the date of issue; and

- the Issuer has the right, at its sole option and, at any time prior to the Maturity Date, to require the holders to convert all or any portion of the outstanding principal amount and any accrued but unpaid Interest thereon into Debtenture Units at the Conversion Price if the daily volume-weighted average price of the common shares of the Issuer on the CSE (or such other stock exchange on which the common shares may be traded at such time) for any 10 day consecutive trading day period is greater than \$0.50, subject to adjustment as provided for in the certificate representing the Debtentures.

Repayment by the Issuer of the amount owing under the Debtentures is secured by a charge over all of the assets of the Issuer. The subscriber to the first tranche of the Financing entered into an agency and inter-lender agreement with the Issuer, pursuant to which the subscriber has been appointed as agent to act on behalf of all subscribers to the Financing as to certain matters relating to the Debtentures, including with respect to enforcement of the security interest.

The Issuer paid a cash finder’s fee of \$13,750 to one finder in connection with the closing of the first and second tranches of the Financing.

2. Provide a general overview and discussion of the activities of management.

See Item 1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

See Item 1 above.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provides details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

See Item 1 above.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None.

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

See Item 1 above.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated November 6, 2019

Swapan Kakumanu
Name of Director/Senior Officer

"Swapan Kakumanu"
Signature

CFO and Director
Official Capacity

Issuer Details Name of Issuer TruTrace Technologies Inc.	For Month End October 2019	Date of Report YY/MM/DD 19/11/06
Issuer Address L120, 2303 4th Street SW		
City/Province/Postal Code Calgary, AB T2S 2S7	Issuer Fax No. 888.241.5996	Issuer Telephone No. 844.656.3629
Contact Name Swapan Kakumanu	Contact Position CFO and Director	Contact Telephone No. 844.656.3629
Contact Email Address swapan@trutrace.co	Web Site Address https://strainsecure.com	